Aridis Pharmaceuticals Balans Gezondheid
Financiële gezondheid criteriumcontroles 0/6
Aridis Pharmaceuticals has a total shareholder equity of $-11.8M and total debt of $3.4M, which brings its debt-to-equity ratio to -28.9%. Its total assets and total liabilities are $6.5M and $18.3M respectively.
Belangrijke informatie
-28.9%
Verhouding schuld/eigen vermogen
US$3.41m
Schuld
| Rente dekkingsratio | n/a |
| Contant | US$35.00k |
| Aandelen | -US$11.80m |
| Totaal verplichtingen | US$18.34m |
| Totaal activa | US$6.53m |
Recente financiële gezondheidsupdates
Recent updates
Aridis Pharmaceuticals announces proposed public stock offering; shares down ~30%
Sep 26Aridis Pharmaceuticals GAAP EPS of -$0.45, revenue of $0.29M
Aug 16Can You Imagine How Aridis Pharmaceuticals' (NASDAQ:ARDS) Shareholders Feel About The 32% Share Price Increase?
Feb 17
Aridis Pharmaceuticals EPS misses by $0.02
Nov 20Aridis Pharmaceuticals (ARDS) Investor Presentation - Slideshow
Oct 31Analyse van de financiële positie
Kortlopende schulden: ARDS has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Langlopende schulden: ARDS has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: ARDS has negative shareholder equity, which is a more serious situation than a high debt level.
Schuld verminderen: ARDS's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balans
Analyse van de cashflow
Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.
Stabiele cash runway: Insufficient data to determine if ARDS has enough cash runway based on its current free cash flow.
Voorspelling contante baan: Insufficient data to determine if ARDS has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.